Medpace price target lowered to $460 from $600 at BMO Capital

BMO Capital lowered the firm’s price target on Medpace (MEDP) to $460 from $600 and keeps a Market Perform rating on the shares after its Q4 results. A a surprise uptick in Q4 metabolic cancellations combined with the ongoing perception of broader AI CRO disintermediation, is weighing on shares, the analyst tells investors in a research note.